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2,5-Anhydro-D-mannitol, an analog of D-fructofuranose, inhibited basal and glucagon-stimulated 
g~ycogenolysis and glucose production in hepatocytes isolated from fed rats. Glucose formation from 
galactose was unaffected by the inhibitor. 2,5Anhydro-D-mannitol-l-phosphate inhibits phosphorylase a
with a K, value of 2.4 mM. This same phosphorylated metabolite accumulates to the extent of 9.2 amol/g 
wet wt in treated hepatocytes uggesting that phosphorolysis is the locus of the inhibition of glucose 
production from glycogen. Our results uggest that 2,5-anhydro-D~mannitol can be used to produce a 
model of hereditary fructose intolerance and that it merits further study as a hypoglycemic agent. 
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1. INTRODUCTION 
As part of a program to evaluate the potential of 
fructose analogs as hypoglycemic agents, we are 
studying the effects of AM on glucose homeostasis 
in Iaboratory animals. The objective of our study 
was to determine the effects of AM on car- 
bohydrate metabolism in the liver. AM has been 
shown to be a substrate for fructokinase (EC 
2.7.1.4) and hexokinase (EC 2.7.1.1) [1,2]. The 
resulting AM-l-P can be phosphorylated by 
phosphofructokinase (EC 2.7.1.11) [3]. Neither 
the mono- nor the diphosphate can be cleaved by 
aIdoIase (EC 4.1.2.13) [4]. On the basis of these in 
vitro enzyme studies, we hypothesized that the ad- 
ministration of AM to isolated hepatocytes would 
result in the intracellular accumulation of mono- 
and diphosphate esters of AM that could have 
marked effects on hepatic glucose output. Data 
here show that AM inhibits glucose production 
from glycogen .
2. MATERIALS AND METHODS 
Bovine serum albumin (Cohn Frac V), enzymes, 
sugars, substrates, and glucagon were purchased 
from Sigma (St.Louis, MO). AM was synthesized 
as in [5]. This synthesis was adapted for the syn- 
thesis of labelled AM [6]. Rat liver phosphorylase 
a (EC 2.4.1.1) was the generous gift of Dr Ted 
Chrisman of Vanderbilt University. 
Ah experiments were done with 200-300 g male 
Sprague-Dawley rats obtained from Blue Spruce 
(Altamont, NY) and fed the stock diet (Charles 
River Rat, Mouse and Hamster Formula, 
Syracuse, NY) ad libitum. 
* To whom reprint requests should be sent 
Abbreviations: AM, 2,S-anhydro-D-mannitol; AM-l-P, 
2,5-anhydro-D-mannitol-l-phosphate; AMBP, 2,5-an- 
hydro-D-mannitol- 1 ,dbiphosphate 
Isolated hepatocytes were prepared from fed 
rats according to [7] as modified in [6,8]. 
Hepatocytes (40-60 mg) were incubated in 25-ml 
poIycarbonate Erlenmeyer flasks with various 
substrates with Krebs-Henseleit buffer in a final 
volume of 2.5 ml. The flasks were gassed with 95% 
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025% COz, sealed with parafilm and incubated at 
37°C and 90 oscillations/min in a shaking water 
bath. At the end of the incubation period suspen- 
sions were deproteinized with 0.5 ml of 3 N per- 
chloric acid, the precipitated protein was pelleted 
by centrifugation and the supernatant was assayed 
for glycogen [9,10], glucose [ll], galactose [12], 
AM phosphates were determined by incubations 
with 131-I]AM followed by ion exchange 
chromatography [6,13]. 
Glycogen phosphorylase assays were performed 
as in [14]; inhibitor constants were determined as 
in [15]. 
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Fig. 1. Effects of AM and glucagon on glucose produc- 
tion (A) and glycogenolysis (B) in hepatocytes isolated 
from a fed rat. Hepatocyte suspensions were incubated 
for 10 min with the indicated concentrations of AM. 
Ghrcagon (0.1 ml of 2.5 x LO-? M glucagon in 0.9% 
saline to give a final concentration of 10m8 M glucagon) 
or saline (0.1 ml of 0.9% saline) was added and incuba- 
tion was continued for 20 min. Rates are expressed as 
pmoi glucose formed/g wet wt hepatocytes (A) andamol 
giycogen broken down/g wet wt hepatocytes (B) during 
the 30-min incubation period. Rates are means + SD for 
2,5-Anhydromanmtol (mM) 
Fig. 2. Effects of AM and galactose on glucose produc- 
tion (A) and glycogenolysis (B) in hepatocytes isolated 
from a fed rat. Hepatocyte suspensions were incubated 
for 60 min with the indicated concentrations of AM and 
with or without 1.0 mM galactose. Rates are expressed 
as pmol glucose formed/g wet wt hepatocytes (A) and 
pmol glycogen broken down/g wet wt hepatocytes (B) 
during the 60-min incubation period. Rates are means + 
triplicate incubations. SD for triplicate incubations. 
3. RESULTS 
In hepatocytes prepared from fed rats, AM in- 
hibited glucose production (fig. 1A) and glycogen 
breakdown (fig.lB) in a dose-dependent manner. 
Substantial inhibition (70%) was observed at 1.0 
mM AM. Stimulation of glucose production 
(fig.lA) and glycogen breakdown (fig.lB) by 
glucagon in control hepatocytes were essentially 
abolished by additions of 1.0 mM AM. 
The ability of hepatocytes prepared from fed 
rats to metabolize galactose was not affected by 
AM. Glucose formation attributable to galactose 
was not inhibited by AM (fig.2A). In addition, 
galactose did not affect the glycogen content of 
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hepatocytes incubated with or without AM 
(fig.2B). 
Hepatocytes from fed aminals treated for 30 min 
with 2.0 mM tritiated AM accumulated 
phosphorylated metabolites of AM; AM-l-P ac- 
cumulated to levels of 9.2 t 2.2 pmol/g wet wt and 
AMBP to levels of 0.43 + 0.23 pmol/g wet wt. 
These levels were not affected by lo-* M glucagon. 
In vitro enzyme studies with isolated rat liver 
phosphorylase a showed that AM-l-P and AMBP 
inhibited phosphorylase a activity. The Km for in- 
organic phosphate was 3.0 mM. Inhibition by 
AM-I-P was competitive with phosphate and a ITi 
value of 2.4 mM was obtained. The inhibition by 
AMBP was slight. 
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4. DISCUSSION REFERENCES 
MetaboIism of AM in hepatocytes appears to be 
similar to the metabolism of fructose in the livers 
of patients with hereditary fructose intolerance 
[l&20]. The analog accumulates in the form of its 
mono- and biphosphate esters, glucose synthesis 
and glycogenolysis are inhibited, glucagon does 
not stimulate glucose production or glycogenolysis 
in AM-treated cells, and the conversion of galac- 
tose into glucose is not inhibited by AM treatment. 
Glucose formation from galactose indicates that 
phosphoglucomutase and glucose-6-phosphatase, 
two enzymes essential for glucose production from 
either galactose or glycogen, are not inhibited in 
hepatocytes incubated with AM. We therefore 
conclude that phosphorolsis is the locus of inhibi- 
tion of glucose production from glycogen. This 
conclusion is further supported by the fact that 
AM-l-P accumulates to levels of 9.2 mM in treated 
hepatocytes, a value well in excess of its Ki value 
for liver phosphorylase Q. 
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This data, taken together with reports of the in- 
hibition of gluconeogenesis by AM [6,21-231 and 
hypoglycemia in AM-treated animals [24] support 
the suggestions that AM can be used to produce a 
model of hereditary fructose intolerance and that 
AM merits further study as a hypoglycemic agent. 
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